Ads
related to: second generation parp inhibitor- About PARP Inhibitors
Learn About How Treatment Works.
Learn About Maintenance Therapy.
- Safety And Side Effects
Read Important Safety Information.
Learn More About A Treatment.
- Treatment Effectiveness
Read About How Treatment Works And
Its Benefits And Risks In Patients.
- Talk To Your Doctor
Get Resources To Help Stay Informed
To Make Your Conversation Easier.
- First-Line Maintenance
Learn About First-Line Treatment.
Download Helpful Resources & Info.
- Tablet Dosing Info
Learn About Tablet Dosing For
An Ovarian Cancer Treatment.
- About PARP Inhibitors
cancer.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
PARP inhibitors are a call of drugs that are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP), which plays a role in repairing DNA in damaged cells. Medical uses of these drugs include the treatment of heritable cancers . [ 1 ]
Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. [1] It is approved for use in China. [2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme.
As the clinical trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clinical investigations, aimed at testing of PARP inhibitors for various non-oncologic indications, will be initiated, in a process called "therapeutic repurposing". [22]
Veliparib (ABT-888) [1] is a potential anti-cancer drug acting as a PARP inhibitor.It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. [3] [4] [5] It is taken by mouth.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Ad
related to: second generation parp inhibitor